2. MAPK/ERK Pathway Cell Cycle/DNA Damage NF-κB
  3. MNK Eukaryotic Initiation Factor (eIF) NF-κB
  4. MNK1/2-IN-10

MNK1/2-IN-10 is an orally active, selective MNK1/MNK2 inhibitor, with an IC50 of 10.84 nM for MNK1 and an IC50 of 12.81 nM for MNK2. MNK1/2-IN-10 inhibits eIF4E phosphorylation, the NF-κB signaling pathway, macrophage polarization, oxidative stress and the production of pro-inflammatory cytokines. MNK1/2-IN-10 alleviates kidney and spleen damage in LPS (HY-D1056)-induced inflammatory mouse models. Anti-inflammatory agent 115 is applicable for research related to acute inflammation.

For research use only. We do not sell to patients.

MNK1/2-IN-10

MNK1/2-IN-10 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

MNK1/2-IN-10 Related Antibodies

Top Publications Citing Use of Products

View All MNK Isoform Specific Products:

View All Isoforms
MNK1 MNK2 MNK

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MNK1/2-IN-10 is an orally active, selective MNK1/MNK2 inhibitor, with an IC50 of 10.84 nM for MNK1 and an IC50 of 12.81 nM for MNK2. MNK1/2-IN-10 inhibits eIF4E phosphorylation, the NF-κB signaling pathway, macrophage polarization, oxidative stress and the production of pro-inflammatory cytokines. MNK1/2-IN-10 alleviates kidney and spleen damage in LPS (HY-D1056)-induced inflammatory mouse models. Anti-inflammatory agent 115 is applicable for research related to acute inflammation[1].

IC50 & Target[1]

MNK1

10.84 nM (IC50)

MNK2

12.81 nM (IC50)

In Vitro

MNK1/2-IN-10 (Compound 13) (48 h) shows low cytotoxicity in RAW 264.7, HEK293T, HUVECs and AML-12 cell lines, with IC50 values ranging from 24.25 to 77.56 μM after 48 h of incubation[1].
MNK1/2-IN-10 (1.25-10 μM; 24 h) inhibits LPS-induced expression of p-eIF4E and iNOS in RAW 264.7 cells in a concentration-dependent manner[1].
MNK1/2-IN-10 (1.25-10 μM; 4 h) concentration-dependently inhibits the LPS-induced expression of p-eIF4E in RAW 264.7 cells[1].
MNK1/2-IN-10 (1.25-10 μM; 24 h) inhibits LPS-induced release of IL-6, TNF-α and MCP-1 in RAW 264.7 cells in a concentration-dependent manner[1].
MNK1/2-IN-10 (1.25-10 μM; 24 h) inhibits lipopolysaccharide (LPS)-induced nitric oxide release in RAW 264.7 cells in a concentration-dependent manner, with the maximum inhibitory effect observed at 10 μM[1].
MNK1/2-IN-10 (10 μM; 24 h) inhibits LPS-induced iNOS expression in RAW 264.7 cells[1].
MNK1/2-IN-10 (1.25-10 μM; 12 h) inhibits LPS-induced activation of the NF-κB pathway in RAW 264.7 cells in a concentration-dependent manner in vitro[1].
MNK1/2-IN-10 (10 μM; 24 h) inhibits LPS-induced nuclear translocation of P65 in RAW 264.7 cells[1].
MNK1/2-IN-10 (2.5-10 μM; 13 h) reduces LPS-induced ROS production in RAW 264.7 cells in a concentration-dependent manner[1].
MNK1/2-IN-10 (10 μM; 14 h) inhibits LPS-induced ROS production in RAW 264.7 cells[1].
MNK1/2-IN-10 (2.5-10 μM; 24 h) restores GSH levels and enhances SOD activity in LPS-stimulated RAW 264.7 cells in a concentration-dependent manner in vitro[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MNK1/2-IN-10 Related Antibodies

Western Blot Analysis[1]

Cell Line: RAW 264.7
Concentration: 10 μM, 5 μM, 2.5 μM, 1.25 μM
Incubation Time: 24 h
Result: Suppressed LPS-induced phosphorylation of eIF4E in a concentration-dependent manner, with maximal suppression at 10 μM.
Suppressed LPS-induced expression of iNOS in a concentration-dependent manner, with maximal suppression at 10 μM.

Immunofluorescence[1]

Cell Line: RAW 264.7
Concentration: 10 μM, 5 μM, 2.5 μM, 1.25 μM
Incubation Time: 2 h (pretreatment); 2 h (LPS stimulation)
Result: Inhibited LPS-induced p-eIF4E expression in a concentration-dependent manner, as shown by reduced green fluorescence intensity.

ELISA Assay[1]

Cell Line: RAW 264.7
Concentration: 10 μM, 5 μM, 2.5 μM, 1.25 μM
Incubation Time: 24 h
Result: Inhibited LPS-induced secretion of IL-6 in a dose-dependent manner.
Inhibited LPS-induced secretion of TNF-α in a dose-dependent manner.
Inhibited LPS-induced secretion of MCP-1 in a dose-dependent manner.

Immunofluorescence[1]

Cell Line: RAW 264.7
Concentration: 10 μM
Incubation Time: 24 h
Result: Diminished iNOS signal in the cytoplasm of LPS-stimulated cells.

Western Blot Analysis[1]

Cell Line: RAW 264.7
Concentration: 10 μM, 5 μM, 2.5 μM, 1.25 μM
Incubation Time: 12 h
Result: Inhibited LPS-induced phosphorylation of P65 in a concentration-dependent manner.
Inhibited LPS-induced phosphorylation of IκBα in a concentration-dependent manner.

Immunofluorescence[1]

Cell Line: RAW 264.7
Concentration: 10 μM
Incubation Time: 12 h (pretreatment); 12 h (LPS stimulation)
Result: Blocked LPS-triggered nuclear translocation of P65, with significantly reduced fluorescence intensity in the nucleus.
Parmacokinetics
Species Dose Route Cmax Tmax T1/2 AUC0-t Bioavailability
Rat[1] 10 mg/kg i.v. 17403.000 ng/mL 1.389 h 10.090 h 82007.297 ng·h/mL /
Rat[1] 200 mg/kg p.o. 5833.000 ng/mL 2.167 h 15.951 h 107535.552 ng·h/mL 6.6 %
In Vivo

MNK1/2-IN-10 (Compound 13) (25-100 mg/kg; p.o.; daily; 16 days) potently alleviates LPS-induced acute inflammation and organ damage in male C57BL/6J mice, with the 100 mg/kg dose demonstrating the strongest efficacy in reducing pro-inflammatory cytokines, suppressing p-eIF4E and iNOS expression, restoring antioxidant function, and improving tissue pathology[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (male, 6−8 weeks old, 18−21 g, LPS-induced)[1]
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: p.o.; daily; 16 days
Result: Significantly reduced LPS-induced kidney and spleen indices, with the 100 mg/kg dose showing the strongest effect.
Improved renal function, reducing serum creatinine and urea nitrogen levels; the 50 and 100 mg/kg doses showed greater improvement than the positive control dexamethasone.
Mitigated LPS-induced kidney pathological changes (tubular dilation, brush border necrosis, vacuolization, structural disruption) and spleen pathological changes (nuclear swelling, cellular edema, inflammatory infiltration, microcirculatory dysfunction).
Significantly reduced serum levels of pro-inflammatory cytokines TNF-α, IL-6, MCP-1, and IL-1β, with the 100 mg/kg dose showing the strongest suppression.
Significantly suppressed p-eIF4E expression and downregulated the M1 macrophage marker iNOS in kidney and spleen tissues, with the 100 mg/kg dose showing the strongest effect.
Restored antioxidant capacity by increasing glutathione and superoxide dismutase levels, and reduced lipid peroxidation by lowering malondialdehyde levels in tissues.
Molecular Weight

520.63

Formula

C25H24N6O3S2
SMILES

O=C(N1CCN(S(CCC)(=O)=O)CC1)C2=CC=C(C3=NN4C(S3)=NC=C4C5=CC=C(C#N)C=C5)C=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

MNK1/2-IN-10 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MNK1/2-IN-10MNKEukaryotic Initiation Factor (eIF)NF-κBMitogen activated protein kinase interacting kinaseMAP kinase interacting kinaseMAPK interacting kinaseNuclear factor-κBNuclear factor-kappaBHUVECsoxidative stressC57BL/6J miceMNK1RAW 264.7NF-κB signalingeIF4E phosphorylationMNK2macrophage polarizationHEK293TInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MNK1/2-IN-10
Cat. No.:
HY-182939
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.